Whole body hyperthermia: A secure procedure for patients with various malignancies?

Intensive Care Medicine

Volumn 25, Issue 9, 1999, Pages 959-965

  Kerner, T ^a,b   Deja, M ^a   Ahlers, O ^a   Loffel J ^a   Hildebrandt, B ^a   Wust, P ^a   Gerlach, H ^a   Riess, H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gas exchange; Hemodynamics; Hyperthermia; Oncology

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; LACTIC ACID;

ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GENERAL ANESTHESIA; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERTHERMIC THERAPY; LABORATORY; LACTATE BLOOD LEVEL; LUNG GAS EXCHANGE; MALE; OXYGEN CONSUMPTION; PATIENT MONITORING; PROSPECTIVE STUDY; SAFETY; TEMPERATURE;

ADULT; ANESTHESIA, INTRAVENOUS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTHERMIA, INDUCED; INFRARED RAYS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; PULMONARY GAS EXCHANGE; SAFETY; STATISTICS, NONPARAMETRIC;

EID: 0032849536     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050989     Document Type: Article

References (24)

1. 1. Wiedemann GJ, d'Oleire F, Knop E, Eleftheriadis S, Bucsky P, Feddersen S, Klouche M, Geisler J, Mentzel M, Schmucker P (1994) Ifosfamide and carboplatin combined with 41.8°C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res 54: 5346-5350
2. 2. Robins HI, Dennis WH, Neville AJ, Shecterle LM, Martin PA, Grossmann J, Davis TE, Neville SR, Gillis WK, Rusy BF (1985) A nontoxic system for 41.8°C whole-body hyperthermia: results of a phase I study using a radiant heat device. Cancer Res 45: 3937-3944
3. 3. Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, d'Oleire F, Longo W, Heiss C (1993) Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 11: 1787-1794
4. 4. Bull JM, Cronau LH, Newman B, Jabboury K, Allen SJ, Ohno S, Smith T, Tonnesen AS (1992) Chemotherapy resistant sarcoma treated with whole body hyperthermia (WBH) combined with 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Int J Hyperthermia 8: 297-304
5. 5. Von Ardenne M (1994) Principles and concept 1993 of the Systemic Cancer Multistep Therapy (sCMT). Extreme whole-body hyperthermia using the infrared-A technique IRATHERM 2000 - selective thermosensitisation by hyperglycemia - circulatory back-up by adapted hyperoxemia. Strahlenther Onkol 170:581-589
6. 6. Robins HI, Woods JP, Schmitt CL, Cohen JD (1994) A new technological approach to radiant heat whole-body hyperthermia. Cancer Lett 79: 137-145
7. 7. Robins HL, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, D'Oleire F, Qu RP, Wilding G, Stewart JA (1997) Phase I clinical trial of melphalan and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 15: 158-164
8. 8. Wiedemann GJ, Robins HI, Katschinski DM, Mentzel M, D'Oleire F, Kutz M, Wagner T (1997) Systemic hyperthermia and ICE chemotherapy for sarcoma patients:rationale and clinical status. Anticancer Res 17: 2899-2902
9. 9. Parks LC, Minaberry D, Smith DP, Neely WA (1979) Treatment of far-advanced bronchogenic carcinoma by extracorporeally induced systemic hyperthermia. J Thorac Cardiovasc Surg 78: 883-892
10. 10. Wiedemann GJ, Roszinski S, Biersack A, Weiss C, Wagner T (1992) Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedi-chloroplatinium cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice. J Cancer Res Clin Oncol 118: 129-135
11. 11. Steinhausen D, Mayer WK, von Ardenne M (1994) Evaluation of systemic tolerance of 42.0°C infrared-A whole-body hyperthermia in combination with hyperglycemia and hyperoxemia. A phase-I study. Strahlenther Onkol 170: 322-334
12. 12. Barry MA, Behnke CA, Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353-2362
13. 13. Pettigrew RT, Galt JM, Ludgate CM, Horn DB, Smith AN (1974) Circulatory and biochemical effects of whole body hyperthermia. Br J Surg 61: 727-730
14. 14. Kim YD, Lake CR, Lees DE, Schuette WH, Bull JM, Weise V, Kopin IJ (1979) Hemodynamic and plasma catecholamine responses to hyperthermic cancer therapy in humans. Am J Physiol 237:H570-H574
15. 15. Barlogie B, Corry PM, Yip E, Lippman L, Johnson DA, Khalil K, Tenczynski TF, Reilly E, Lawson R, Dosik G, Rigor B, Hankenson R, Freireich EJ (1979) Total body hyperthermia with and without chemotherapy for advanced human neoplasms. Cancer Res 39: 1481-1489
16. 16. Ostrow S, van Echo D, Whitacre M, Aisner J, Simon R, Wiernik PH (1981) Physiologic response and toxicity in patients undergoing whole-body hyperthermia for the treatment of cancer. Cancer Treat Rep 65: 323-325
17. 17. Faithfull NS, Reinhold HS, van den Berg AP, van Rhoon GC, van der Zee J, Wike-Hooley JL (1984) Cardiovascular changes during whole body hyperthermia treatment of advanced malignancy. Eur J Appl Physiol 53: 274-281
18. 18. Robins H, Hugander A, Besozzi M, Schmitt CL, Martin PA, Zager LV, Grossman J (1991) Beta-blockade during whole-body hyperthermia: a toxicity study in the dog. Int J Hyperthermia 7: 263-270
19. 19. Berry JM, Michalsen A, Nagle V, Bull JM (1997) The use of esmolol in whole-body hyperthermia:cardiovascular effects. Int J Hyperthermia 13: 261-268
20. 20. Lees DE, Kim YD, Bull JM, Whang-Peng J, Schuette W, Smith R, Macnamara TE (1980) Anesthetic management of whole-body hyperthermia for the treatment of cancer. Anesthesiology 52: 418-428, 1980
21. 21. Foxall PJD, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL (1997) Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy. Clin Cancer Res 3: 1507-1518
22. 22. Brauer LP, Prieshof B, Wiedemann GJ, Weiss C, Kriz W, Schramm U, Robins HI, Pagel H (1998) Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity. J Cancer Res Clin Oncol 124: 549-554
23. 23. Page RL, Meyer RE, Thrall DE, Dewhirst MW (1987) Cardiovascular and metabolic response of tumour-bearing dogs to whole body hyperthermia. Int J Hyperthermia 3: 513-525
24. 24. Yoshitake S, Noguchi T, Hoashi S, Honda N (1998) Changes in intramucosal pH and gut blood flow during whole body heating in a porcine model. Int J Hyperthermia 14: 285-291